Fujimori Kogyo Co., Ltd.

Chisso Corporation

Kazuya Hosokawa

Tomoko Wada

Toyoaki Suzuki

Masanori Nagata

Hisayo Kaneko

Takao Sato

Takaaki Hasegawa

Yasuto Ishikawa

Maki Terada

Tomoka Nagasato

Masashi Fukasawa

Taro Kondo

Maki Gonda

A method for analyzing thrombogenic capacity or blood coagulation capacity, the method comprising adding calcium, a blood coagulation factor XII (FXII) inhibitor, and a kallikrein inhibitor to blood collected with a blood collection tube containing sodium citrate, to allow initiation of blood coagulation reaction, is provided. Preferably, heparin, heparan sulfate, and tissue factor are further added to the blood, and thrombogenic capacity or blood coagulation capacity is analyzed.

Blood collection tube, reagent, and method for analyzing blood characteristics using same

A blood coagulation test device includes: a container into which a test-object blood is placed; a stirring part for stirring the test-object blood in the container; an elastic body being connected to the stirring part and capable of deforming in response to a force received through stirring of the test-object blood from the stirring part; a control unit for transmitting a predetermined rotary motion to the stirring part and causing the stirring part to rotate in a reciprocating manner in a circumferential direction by rotating the elastic body in a reciprocating manner about an axis of the stirring part as a rotation axis and controlling the reciprocating rotation at a position separated by a predetermined diameter from the rotational axis; and a measurement unit for measuring a rotation angle pertaining to the reciprocating rotation of the stirring part.

Blood coagulation test device and blood coagulation test method

The present invention addresses a problem in which, when examining blood properties in measurements of thrombus formation capacity and platelet function or the like, measurement data is changed as a result of sedimentation of blood in reservoirs during measurement. An erythrocyte membrane ion transport inhibitor, such as disodium 4,4'-dinitrostilbene-2,2&#x2032;-disulfonate (DNDS) or 4,4&#x2032;-diisothiocyanatostilbene-2,2&#x2032;-disulfonic acid (DIDS), is used to inhibit erythrocyte sedimentation, and accurate measurement data is obtained.

Erythrocyte sedimentation inhibitor

A microchip for testing a blood property, comprising first and second channels for allowing a blood sample(s) to flow inside, wherein the first channel has a first reaction section coated with collagen and tissue thromboplastin; and said second channel has a second reaction section, wherein the second section has been coated with collagen and tissue thromboplastin the amount of which is equivalent to or smaller than the amount of tissue thromboplastin on said first channel, or the second section has been coated with collagen but not with tissue thromboplastin.

Microchip for assay of blood properties, and device for assay of blood properties

Blood observation device

A method of monitoring thrombus formation is described, which comprises flowing anticoagulated blood into a thrombus formation chamber, in at least a part of which a thrombus formation inducer inducing thrombus formation is provided, while releasing the anticoagulant treatment or promoting blood coagulation to thereby monitor thrombus formation in the thrombus formation chamber.

Method for monitoring thrombus formation

An apparatus for monitoring thrombus formation wherein anticoagulated blood is flown through a channel simulating a blood vessel while releasing the anticoagulant treatment or promoting blood coagulation to thereby monitor thrombus formation. This apparatus for monitoring thrombus formation comprises: a thrombus formation chamber in at least a part of which a thrombus formation inducer inducing thrombus formation is provided; an inlet tube which is connected to the thrombus formation chamber and through which blood is flown into the thrombus formation chamber; and a drug tube which is connected to the inlet tube and through which a drug releasing the anticoagulant treatment or a drug promoting blood coagulation is supplied.

Apparatus for monitoring thrombus formation

A microchip for measuring platelet function by allowing blood to flow through a channel to induce platelet aggregation, wherein the microchip has a channel provided inside thereof, wherein at least a part of the channel is coated with collagen for allowing adhesion of platelets; a plurality of walls extend along the direction of the flow of blood in the channel and divide the width of the channel to form a channel dividing section; and the walls are treated to have a surface roughness (Ra) of 10 to 200 nm.

Microchip for platelet examination and platelet examination device using same

A microchip comprising therein a first channel which allows inflow of a first liquid selected from whole blood, platelet-rich plasma and a drug-treated liquid thereof, a second channel connected to the first channel, which allows inflow of a second liquid containing an agent that is reactive with the first liquid, and a merged channel extended from the connection portion of the first channel with the second channel, wherein, in the merged channel, a stirring section having a stirring bar for mixing the first liquid with the second liquid is provided; and a blood monitoring device using the same.

Microchip and blood monitoring device

An apparatus for monitoring thrombus formation wherein anticoagulated blood is flown through a channel simulating a blood vessel while releasing the anticoagulant treatment or promoting blood coagulation to thereby monitor thrombus formation. This apparatus for monitoring thrombus formation comprises: a thrombus formation chamber in at least a part of which a thrombus formation inducer inducing thrombus formation is provided; an inlet tube which is connected to the thrombus formation chamber and through which blood is flown into the thrombus formation chamber; and a drug tube which is connected to the inlet tube and through which a drug releasing the anticoagulant treatment or a drug promoting blood coagulation is supplied. A method of monitoring thrombus formation which comprises flowing anticoagulated blood into a thrombus formation chamber, in at least a part of which a thrombus formation inducer inducing thrombus formation is provided, while releasing the anticoagulant treatment or promoting blood coagulation to thereby monitor thrombus formation.

Apparatus for monitoring thrombus formation and method of monitoring thrombus formation

A thrombin mutant in which at least serine at position 205 among amino acids in the active center of the thrombin B chain has been replaced with another amino acid, and further at least one of the following replacements have been introduced: (I) replacement of arginine at position 89 in the B-chain with another amino acid; (II) replacement of threonine at position 69 or serine at position 22 in the B-chain with another amino acid; (III) replacement of alanine at position 200 in the B-chain with another amino acid; and (IV) replacement of lysine at position 65 in the B-chain with threonine.

Thrombin mutant

A thrombin derivative having a lowered fibrinogen activity, a process for producing thereof, an anhydrothrombin derivative having a lowered fibrinogen activity, and a process for producing thereof are provided. This invention is to provide a thrombin derivative formed by modifying carboxyl group(s) of the thrombin and an anhydrothrombin derivative formed by modifying carboxyl group(s) of the anhydrothrombin. The thrombin derivative can be utilized as a composition for inducing platelet aggregation and further as a reagent of specific aggregation for clinical testing and the like. By affinity chromatography using carboxyl group(s) bound with anhydrothrombin as a ligand, it is made possible to carry out necessary purification with high selectivity relative to the blood coagulation factor VIII. Further, the anhydrothrombin derivative which results from modifying carboxyl group(s) of anhydrothrombin produces sufficient antithrombogenic effects at a smaller amount as compared with the previous anhydrothrombin and, therefore, can be utilized as an agent for inhibiting the thrombogenesis.

THROMBIN DERIVATIVES AND PROCESS FOR PRODUCING THE SAME, ANHYDROTHROMBIN DERIVATIVES AND PROCESS FOR PRODUCING THE SAME, PLATELET AGGLUTINATION-INDUCING COMPOSITIONS, METHOD OF INDUCING PLATELET AGGLUTINATION, CLINICAL TEST REAGENTS, CLINICAL TEST METHOD, THROMBOSIS INHIBITORS, ADSORBENT AND PROCESS FOR PRODUCING THE SAME

A method for the refinement of a thrombin substrate, characterized by comprising therein a step of affinity chromatography formed by using an affinity adsorbent having as a ligand a thrombin or thrombin analogue deprived of nucleophilicity (activity) without causing stereostructure to the linkage with a substrate is disclosed.

Method for purifying thrombin substrate and/or inhibitors or method for eliminating the same

A method for a synthesis of anhydrothrombin is provided which features a short process, an easy procedure, and high yields. The method comprises

Growing community of inventors

Tokyo, Japan

Kazuya Hosokawa